Kidney Disease News and Research

RSS

Rockwell Medical third quarter sales increases 4.1% to $14.7 million

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported third quarter 2010 results today.

4 Nov 2010

Kidney disease registry could help clinicians to evaluate treatment strategies for CKD patients

A registry of health care information on patients with mild to moderate chronic kidney disease (CKD) could help physicians improve care for affected individuals, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The results suggest that officials could use such a registry to develop a national surveillance system to identify and track various aspects of CKD.

4 Nov 2010

Researchers to develop multidisciplinary approach to help kidney disease patients adhere to BP medications

Researchers at the University of Cincinnati (UC) and the Cincinnati Veterans Affairs (VA) Medical Center have found that about one-third of chronic kidney disease patients who are prescribed therapies for high blood pressure do not often adhere to treatments.

4 Nov 2010

Bolder BioTechnology receives $1.2 million in Qualifying Therapeutic Discovery Project Grants

Bolder BioTechnology, Inc. today announced that it has been awarded a total of $1.2 million in Qualifying Therapeutic Discovery Project Grants. Grants were awarded for qualified investments under the Qualifying Therapeutic Discovery Project Tax Credit Program, which authorized up to $1 billion in tax credits or grants to biopharmaceutical companies with 250 or fewer employees.

4 Nov 2010

CorMedix awarded $488,959 QTDP program grant to develop Neutrolin and Deferiprone clinical programs

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it has been awarded two grants totaling $488,959 under the qualifying therapeutic discovery project ("QTDP") program established under Section 48D of the Internal Revenue Code. These grants were awarded based on applications CorMedix submitted for both its Neutrolin® and Deferiprone programs.

4 Nov 2010

Spectrum Pharmaceuticals receives $977,900 grant under QTDP program

Spectrum Pharmaceuticals, Inc. a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it has been awarded grants totaling $977,900 under the Qualifying Therapeutic Discovery Project (QTDP) Program administered under section 48D of the Internal Revenue Code.

4 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

Amgen outlines key recommendations for implementing approval pathway for biosimilars

Amgen Senior Vice President of Research and Development Joe Miletich, M.D., Ph.D., will urge members of a U.S. Food and Drug Administration (FDA) panel charged with implementing a pathway for biosimilars to establish approval standards that ensure patient safety and follow a science-based approach.

3 Nov 2010

Eli Lilly's new research center to focus on diabetes in China

Eli Lilly and Company announced today plans to open a research center focused on diabetes in China, where the incidence of the disease has reached epidemic proportions.

2 Nov 2010

FDA approves cancer drug Afinitor for treatment of rare genetic disorder

The U.S. Food and Drug Administration approved the cancer drug Afinitor (everolimus) on Friday to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS), a rare genetic disorder. This approval was for treatments of SEGA that can not be treated with surgery.

1 Nov 2010

Summit discusses value, cost-effectiveness of America's investment in wellness and prevention

America's historic investment in wellness and prevention mandated under the Affordable Care Act may not always save money – but it will be worth it.

30 Oct 2010

LRI's innovative discovery to predict lupus receives license for clinical laboratory development

A discovery made by Lupus Research Institute-funded investigator Emily Baechler Gillespie, PhD, at the University of Minnesota has been licensed to a major clinical laboratory for development and could soon result in a test that quickly and easily enables patients and their physicians to determine when a lupus flare is imminent.

29 Oct 2010

Access to kidney transplantation increases for elderly patients

Elderly patients with kidney failure get kidney transplants more often than they did a decade ago, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The results suggest that the chances of receiving a kidney transplant are better than ever for an older patient who needs one.

29 Oct 2010

Low birth weight linked to poor growth in children with CKD

The lower the birth weight, the greater the chance of poor growth rate in children with chronic kidney disease (CKD), according to a new study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

29 Oct 2010

Rockwell receives SFP patent for GMP formulation

Rockwell Medical a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has received notice from the U.S. Patent and Trademark Office for patent issuance on its proprietary GMP formulation for Soluble Ferric Pyrophosphate (SFP), the Company's lead-drug candidate for treating iron deficiency anemia in ESRD patients.

27 Oct 2010

Tengion presents data on Neo-Kidney Augment at Transplantation's Annual Scientific Exchange

Tengion, Inc. a leader in regenerative medicine, presented new data on Saturday, October 23, 2010 in a podium presentation at the American Society for Transplantation's Annual Scientific Exchange in Orlando, FL. The presentation highlighted new early data from Tengion's Neo-Kidney Augment development program demonstrating promising improvements in kidney function with an autologous cellular therapy approach to kidney regeneration in a canine model of chronic kidney disease.

26 Oct 2010

Amgen reports $3,816 million for 2010 third quarter revenue

Amgen reported revenue unchanged for the third quarter of 2010 at $3,816 million versus $3,812 million for the third quarter of 2009.

26 Oct 2010

New disease map resource can reduce MRSA infection in hospitalized patients

Gary A. Puckrein, Ph.D., CEO of the National Minority Quality Forum, and Gary Doern, Ph.D., nationally recognized infectious disease expert, will host the launch of the national MRSA Atlas by way of a webinar.

25 Oct 2010

Social networks important for maintaining dialysis patients' health: Study

Dialysis patients with little social support from friends and family are more likely to ignore doctors' orders, experience a poorer quality of life, and die prematurely, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology. The results suggest strong social networks are important for maintaining dialysis patients' health.

22 Oct 2010

Biomarkers can improve ability to identify patients at high risk of CKD: Study

Measuring three biomarkers in a single blood sample may improve physicians' ability to identify patients at high risk of developing chronic kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

22 Oct 2010

Kidney Disease News and Research

Rockwell Medical third quarter sales increases 4.1% to $14.7 million

Kidney disease registry could help clinicians to evaluate treatment strategies for CKD patients

Researchers to develop multidisciplinary approach to help kidney disease patients adhere to BP medications

Bolder BioTechnology receives $1.2 million in Qualifying Therapeutic Discovery Project Grants

CorMedix awarded $488,959 QTDP program grant to develop Neutrolin and Deferiprone clinical programs

Spectrum Pharmaceuticals receives $977,900 grant under QTDP program

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Amgen outlines key recommendations for implementing approval pathway for biosimilars

Eli Lilly's new research center to focus on diabetes in China

FDA approves cancer drug Afinitor for treatment of rare genetic disorder

Summit discusses value, cost-effectiveness of America's investment in wellness and prevention

LRI's innovative discovery to predict lupus receives license for clinical laboratory development

Access to kidney transplantation increases for elderly patients

Low birth weight linked to poor growth in children with CKD

Rockwell receives SFP patent for GMP formulation

Tengion presents data on Neo-Kidney Augment at Transplantation's Annual Scientific Exchange

Amgen reports $3,816 million for 2010 third quarter revenue

New disease map resource can reduce MRSA infection in hospitalized patients

Social networks important for maintaining dialysis patients' health: Study

Biomarkers can improve ability to identify patients at high risk of CKD: Study

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News